Tafluprost Santen

What Is Tafluprost Santen and What Is It Used For?

Tafluprost Santen is a preservative-free prostaglandin F2-alpha analogue eye drop that lowers intraocular pressure (IOP) by enhancing the uveoscleral outflow of aqueous humor. It is indicated for the reduction of elevated intraocular pressure in adult patients with open-angle glaucoma and ocular hypertension, either as monotherapy or in combination with other IOP-lowering medications.

Tafluprost is a fluorinated synthetic analogue of prostaglandin F2-alpha and acts as a highly selective, full agonist of the prostaglandin FP receptor. By binding to FP receptors in the ciliary body of the eye, tafluprost initiates a cascade of biochemical changes that remodel the extracellular matrix of the uveoscleral outflow pathway, thereby increasing the drainage of aqueous humor from the anterior chamber and reducing intraocular pressure.

Tafluprost Santen is approved for two primary clinical indications. Open-angle glaucoma is a chronic, progressive optic neuropathy in which elevated intraocular pressure contributes to damage of the optic nerve and retinal ganglion cells, leading to characteristic visual field loss and, ultimately, blindness if untreated. Ocular hypertension refers to intraocular pressure above the statistical normal range (typically greater than 21 mmHg) in the absence of detectable glaucomatous damage – a condition that significantly elevates the risk of developing glaucoma over time and often warrants prophylactic treatment.

According to the European Glaucoma Society (EGS) Terminology and Guidelines for Glaucoma and the American Academy of Ophthalmology (AAO) Preferred Practice Pattern, prostaglandin analogues including tafluprost are recommended as first-line monotherapy for the majority of patients with open-angle glaucoma. This recommendation is based on their strong IOP-lowering efficacy (approximately 25–35% reduction from baseline), favorable once-daily dosing, and minimal systemic side effect profile compared with other pressure-lowering drug classes such as beta-blockers or carbonic anhydrase inhibitors.

What distinguishes Tafluprost Santen from other prostaglandin analogues is its preservative-free formulation. The absence of benzalkonium chloride (BAK) – a commonly used preservative associated with tear film instability, corneal epithelial damage, and ocular surface inflammation – makes Tafluprost Santen particularly suitable for long-term glaucoma management, patients with pre-existing dry eye disease, contact lens wearers, and individuals who have experienced intolerance to preservative-containing eye drops.

How Does Tafluprost Work?

Tafluprost is an inactive prodrug that is hydrolysed by corneal esterases to its active acid metabolite, tafluprost acid, shortly after topical administration. Once activated, the metabolite binds with high affinity and selectivity to prostaglandin FP receptors located on the smooth muscle of the ciliary body. This receptor activation triggers intracellular signaling that upregulates matrix metalloproteinases, which in turn remodel the extracellular matrix of the ciliary muscle bundles and widen the spaces between them. The result is enhanced drainage of aqueous humor through the uveoscleral outflow pathway – an alternative drainage route that bypasses the conventional trabecular meshwork.

The IOP-lowering effect of tafluprost begins approximately 2–4 hours after the first application, with maximum pressure reduction occurring around 12 hours post-instillation. Clinical studies have demonstrated that this IOP reduction is maintained for at least 24 hours, making once-daily evening dosing clinically effective. Evening application is generally preferred because it coincides with the physiologic nocturnal rise in IOP, providing 24-hour pressure control with minimal diurnal fluctuation. Tafluprost is rapidly cleared from the systemic circulation with a plasma half-life of approximately 20–30 minutes, explaining its excellent systemic safety profile.

Why Choose a Preservative-Free Formulation?

Many conventional ophthalmic preparations contain benzalkonium chloride (BAK) as a preservative to prevent microbial contamination of the multi-dose bottle. While effective as an antimicrobial, BAK has well-documented cytotoxic effects on the corneal and conjunctival epithelium. Chronic exposure to BAK – as occurs with daily glaucoma therapy over many years – has been linked to tear film instability, goblet cell loss, subclinical conjunctival inflammation, and worsening of dry eye disease. These ocular surface changes not only impair quality of life through symptoms of burning, stinging, and foreign body sensation, but can also compromise the success of future glaucoma filtration surgery.

By eliminating BAK entirely, Tafluprost Santen offers a meaningful benefit to the many glaucoma patients who would otherwise develop or experience worsening ocular surface disease from long-term therapy. Published comparative studies have demonstrated significantly better ocular surface health markers (tear break-up time, corneal fluorescein staining, conjunctival hyperaemia scores) with preservative-free tafluprost compared with preservative-containing prostaglandin analogues, without compromising IOP-lowering efficacy.

What Should You Know Before Using Tafluprost Santen?

Do not use Tafluprost Santen if you are allergic to tafluprost or any excipient. Inform your ophthalmologist about any history of uveitis, macular edema, eye surgery, severe asthma, or pregnancy. Tafluprost Santen is not recommended during pregnancy or breastfeeding, nor in children and adolescents under 18 years due to insufficient data.

Contraindications

Tafluprost Santen is contraindicated in patients with a known hypersensitivity to tafluprost or to any of the excipients in the formulation. Signs of a hypersensitivity reaction may include severe ocular redness, eyelid swelling, itching, rash around the eyes, or in rare cases systemic allergic symptoms such as wheezing or angioedema. If any of these symptoms develop after instillation, stop using the product immediately and seek medical advice.

Warnings and Precautions

Before starting treatment with Tafluprost Santen, discuss the following points with your ophthalmologist or pharmacist, particularly if any of them apply to you:

• Iris and periorbital pigmentation changes: Tafluprost may gradually and permanently increase brown pigmentation of the iris and darken the skin around the eyes. This is most pronounced in patients with mixed-colored eyes and can be cosmetically noticeable if only one eye is treated.
• Eyelash changes: The medication commonly causes gradual lengthening, thickening, darkening, and increased number of eyelashes on the treated side. These changes usually reverse after treatment is stopped.
• Aphakia and pseudophakia: Patients who are aphakic (without a natural lens) or pseudophakic (with intraocular lens implant) with a torn posterior lens capsule, or those with known risk factors for cystoid macular edema, should use tafluprost with caution because of a small risk of precipitating macular edema.
• Active intraocular inflammation: Patients with active uveitis or iritis should avoid tafluprost or use it only under close specialist supervision, as prostaglandin analogues may exacerbate intraocular inflammation.
• Herpetic keratitis: Tafluprost should be used with caution in patients with a history of herpes simplex virus (HSV) keratitis, as reactivation has been reported with prostaglandin analogues.
• Severe or uncontrolled asthma: Although the systemic absorption of tafluprost is minimal, patients with severe asthma should be monitored, as rare cases of asthma exacerbation have been associated with ocular prostaglandin therapy.
• Periorbital fat atrophy: Long-term use of prostaglandin analogues, including tafluprost, has been associated with deepening of the upper eyelid sulcus, loss of periorbital fat, and a sunken appearance (prostaglandin-associated periorbitopathy or PAP). Patients treated bilaterally may not notice asymmetry.

Pregnancy and Breastfeeding

Pregnancy: There are no adequate data on the use of tafluprost in pregnant women. Prostaglandins may affect vascular tone in the fetus and animal studies have shown reproductive toxicity at clinically relevant doses. Tafluprost Santen should not be used during pregnancy unless clearly necessary and only when the potential benefit to the mother justifies the risk to the fetus. Women of childbearing potential should use adequate contraception during treatment.

Breastfeeding: It is unknown whether tafluprost or its metabolites are excreted in human breast milk. Animal studies have shown that tafluprost and its metabolites do pass into breast milk. A risk to the nursing infant cannot be excluded, and therefore Tafluprost Santen should not be used during breastfeeding.

Fertility: There are no data on the effect of tafluprost on human fertility. Animal studies at clinically relevant doses have not shown impaired fertility.

Pediatric Use

The safety and efficacy of Tafluprost Santen in children and adolescents below 18 years of age have not been established. Tafluprost Santen is not recommended in this population. For childhood glaucoma, alternative prostaglandin analogues such as latanoprost (which has specific pediatric indication) may be preferred.

Driving and Operating Machinery

Instillation of eye drops can cause temporary blurred vision that may affect the ability to drive or operate machinery. Wait until your vision has cleared before driving or engaging in tasks that require clear vision. This effect is usually brief and resolves within a few minutes of application.

How Does Tafluprost Santen Interact with Other Drugs?

Tafluprost Santen has a low potential for systemic drug interactions because of minimal systemic absorption. However, clinically relevant ocular interactions exist with other prostaglandin analogues (which may paradoxically raise IOP) and other topical eye medications. If using multiple eye drops, wait at least 5 minutes between each application.

Because tafluprost is administered topically to the eye with only minimal systemic absorption, significant pharmacokinetic interactions with oral or systemic medications are not expected. No specific drug interaction studies with systemic medicinal products have been performed. The primary interactions of clinical importance involve other ophthalmic medications applied to the same eye.

If your ophthalmologist prescribes more than one topical eye medication, apply them at least 5 minutes apart. Instilling drops too close together dilutes the first medication and may reduce its absorption. Generally, aqueous solutions are applied first, followed by suspensions or ointments. If you wear contact lenses, your doctor will advise on optimal timing relative to lens insertion and removal.

Always inform your healthcare provider about all prescription medications, over-the-counter products, herbal supplements, and eye drops you use – including any used by previous prescribers or bought while travelling abroad. Even products that seem unrelated, such as inhalers for asthma or chronic obstructive pulmonary disease, should be mentioned because the underlying condition may influence your suitability for prostaglandin therapy.

What Is the Correct Dosage of Tafluprost Santen?

The recommended dose is one drop of Tafluprost Santen in the conjunctival sac of the affected eye(s) once daily in the evening. Do not exceed once-daily dosing. Each single-dose container is for single use and should be discarded immediately after use, even if solution remains. Dosage is the same for adults and elderly patients; not recommended in children under 18.

Always use Tafluprost Santen exactly as your ophthalmologist has prescribed. If you are unsure, consult your doctor or pharmacist. Consistency of administration is essential to maintain stable 24-hour IOP control and to minimize fluctuations that can contribute to progressive optic nerve damage.

Adults (Including Elderly)

Elderly Patients

Hepatic and Renal Impairment

Children and Adolescents

How to Apply Tafluprost Santen Eye Drops

Correct application is essential to ensure adequate ocular absorption, minimize contamination, and reduce systemic side effects. Follow these steps carefully:

1. Wash your hands thoroughly with soap and water and dry them with a clean towel.
2. Open the foil pouch and remove one single-dose container. Keep the remaining containers inside the original pouch to protect them from light and evaporation.
3. Hold the single-dose container upright and twist off the cap. Avoid touching the dropper tip to prevent bacterial contamination of the eye or solution.
4. Tilt your head back and gently pull down the lower eyelid of the affected eye with one finger to form a small pocket (conjunctival sac).
5. Position the container close to, but not touching, the eye. Squeeze the container gently so that exactly one drop falls into the pocket formed by the lower eyelid.
6. Close the eye gently and press a finger against the inner corner of the eye (nasolacrimal occlusion) for approximately 1 minute. This reduces drainage into the nasal cavity and minimizes systemic absorption and side effects.
7. If treating both eyes, use the same single-dose container to apply a drop to the other eye – the volume is sufficient for both eyes when used within a few minutes.
8. Discard the single-dose container immediately after use, even if solution remains inside. The container is NOT designed for re-use and the unpreserved solution can become contaminated.

Missed Dose

If you forget to apply your evening dose, apply one drop as soon as you remember the same evening. If it is already the next morning, skip the missed dose and resume your normal once-daily evening schedule the following evening. Do not apply a double dose to make up for a missed one – doubling the dose does not provide additional IOP reduction and may increase side effects.

Overdose

If excess drops are inadvertently instilled, mild transient ocular irritation, conjunctival hyperaemia, and increased tearing may occur. These effects typically resolve spontaneously without specific treatment. Rinsing the eye with sterile saline or clean water is generally not necessary.

If Tafluprost Santen is accidentally swallowed (for example by a child), contact your doctor, emergency department, or poison control center immediately. Systemic overdose is unlikely to cause serious harm due to the very small drug quantity per container, but supportive care may be indicated. Symptoms could theoretically include nausea, flushing, headache, or transient cardiovascular changes.

What Are the Side Effects of Tafluprost Santen?

The most common side effects are ocular and include eye redness (conjunctival hyperaemia), eye irritation, eye pain, iris pigmentation changes, and eyelash changes. Because Tafluprost Santen is preservative-free, ocular surface tolerability is generally better than preservative-containing alternatives. Serious side effects such as macular edema or worsening asthma are uncommon.

Like all medicines, Tafluprost Santen can cause side effects, although not everyone will experience them. Most side effects are mild to moderate in intensity, occur locally in the eye, and often diminish with continued use. The side effect frequencies below are derived from EMA Summary of Product Characteristics data and post-marketing surveillance reports.

Preservative-Free Advantage for Ocular Surface

Clinical studies comparing preservative-free tafluprost with preservative-containing prostaglandin analogues have consistently demonstrated improved ocular surface health markers, including better tear film stability, reduced corneal fluorescein staining, lower conjunctival hyperaemia scores, and fewer patient-reported symptoms of dryness and stinging. This favorable tolerability profile is particularly relevant for patients requiring long-term glaucoma therapy, those with concomitant dry eye disease, and individuals who have previously been intolerant of preservative-containing formulations.

Reporting of Suspected Side Effects

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to national reporting systems such as the FDA MedWatch programme (United States), the MHRA Yellow Card scheme (United Kingdom), or the EMA EudraVigilance network (European Union).

How Should You Store Tafluprost Santen?

Store unopened foil pouches in a refrigerator at 2–8 °C (36–46 °F). After opening the pouch, store the single-dose containers in the pouch at room temperature below 25 °C (77 °F) and use within 28 days. Each single-dose container is for single use and must be discarded immediately after use. Keep out of reach of children.

Proper storage of Tafluprost Santen is essential to maintain sterility (because of the absence of preservatives) and chemical stability of the active substance. The preservative-free single-dose format places additional importance on careful handling and prompt discard of used containers.

Keep Tafluprost Santen in a place where it cannot be seen or reached by children. Do not dispose of medicines via household waste or wastewater. Ask your pharmacist how to dispose of unused or expired medicines – these measures help protect the environment and prevent accidental exposure by others.

What Does Tafluprost Santen Contain?

Each milliliter of Tafluprost Santen eye drops contains 15 micrograms of the active substance tafluprost. The formulation is preservative-free (no benzalkonium chloride) and is supplied in single-dose low-density polyethylene containers. Each single-dose container delivers approximately 0.3 mL, sufficient for one dose in both eyes.

Active Ingredient

The active substance is tafluprost, a synthetic fluorinated analogue of prostaglandin F2-alpha. Each 1 mL of eye drop solution contains 15 micrograms of tafluprost. Each single-dose container contains 0.3 mL of solution, delivering approximately 4.5 micrograms of tafluprost per container – sufficient for one or both eyes.

Inactive Ingredients (Excipients)

Tafluprost Santen is a preservative-free formulation. The other ingredients maintain physiologic pH, isotonicity, and chemical stability without the need for antimicrobial preservatives:

• Glycerol – tonicity agent and mild lubricant
• Sodium dihydrogen phosphate dihydrate – pH buffer
• Disodium edetate – chelating agent that stabilises the active substance
• Polysorbate 80 – solubiliser for tafluprost
• Hydrochloric acid and/or sodium hydroxide – used in small amounts for pH adjustment
• Water for injections – vehicle/solvent

Important: Tafluprost Santen does not contain benzalkonium chloride or any other preservative. This is a key feature of the product and distinguishes it from most multi-dose prostaglandin analogues on the market.

Appearance and Packaging

Tafluprost Santen is a clear, colorless aqueous solution supplied in single-dose, low-density polyethylene (LDPE) containers with twist-off caps. The single-dose containers are packed in sealed laminated aluminum foil pouches to protect them from light and evaporation. Each pouch typically contains 10 single-dose containers. Pack sizes vary by market but commonly include 30 single-dose containers (3 pouches) or 90 single-dose containers (9 pouches). Not all pack sizes may be available in all markets.